Overview

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC

Status:
NOT_YET_RECRUITING

Trial end date:
2029-09-20

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the effectiveness and safety of combining moderately hypofractionated radiotherapy with chemotherapy and anti-PD-1 antibodies as a neoadjuvant treatment for high-risk locally advanced rectal cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Zhongshan Hospital

Treatments:

Drug Therapy
Immunotherapy
Surgical Procedures, Operative